Filtered By:
Condition: Asthma
Drug: Aspirin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 227 results found since Jan 2013.
The chronic rhinosinusitis practice parameter
Ann Allergy Asthma Immunol. 2023 Sep;131(3):307-310. doi: 10.1016/j.anai.2022.12.022. Epub 2022 Dec 17.ABSTRACTThe Allergy-Immunology Joint Task Force on Practice Parameters has published the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) guidelines for the medical management of chronic rhinosinusitis with nasal polyposis (CRSwNP). The practice parameter provides evidence-based guidelines on the use of intranasal corticosteroids (INCS) and biologics for CRSwNP, and aspirin therapy after desensitization (ATAD) for the management of aspirin-exacerbated respiratory disease (AERD). Evidence on surge...
Source: Annals of Allergy, Asthma and Immunology - September 5, 2023 Category: Allergy & Immunology Authors: So Lim Kim Matthew A Rank Anju Tripathi Peters Source Type: research
Eosinophilic Granulomatosis with Polyangiitis Presenting as Aspirin Exacerbated Respiratory Disease
Ann Allergy Asthma Immunol. 2023 Jul 22:S1081-1206(23)00519-7. doi: 10.1016/j.anai.2023.07.014. Online ahead of print.NO ABSTRACTPMID:37487803 | DOI:10.1016/j.anai.2023.07.014
Source: Annals of Allergy, Asthma and Immunology - July 24, 2023 Category: Allergy & Immunology Authors: Sabrina D Herzberg Alyssa M Bosso Neel R Sangal John V Bosso Source Type: research
Perioperative mepolizumab in aspirin-exacerbated respiratory disease does not prevent nasal polyp regrowth
Ann Allergy Asthma Immunol. 2023 Jun 17:S1081-1206(23)00442-8. doi: 10.1016/j.anai.2023.06.017. Online ahead of print.NO ABSTRACTPMID:37336258 | DOI:10.1016/j.anai.2023.06.017
Source: Annals of Allergy, Asthma and Immunology - June 19, 2023 Category: Allergy & Immunology Authors: Andrew D Supron Regan W Bergmark Rachel E Roditi Kathleen M Buchheit Source Type: research
Characterization of Alcohol-Induced Respiratory Symptoms in Aspirin-Exacerbated Respiratory Disease (AERD)
Ann Allergy Asthma Immunol. 2023 Jun 9:S1081-1206(23)00409-X. doi: 10.1016/j.anai.2023.06.002. Online ahead of print.NO ABSTRACTPMID:37302527 | DOI:10.1016/j.anai.2023.06.002
Source: Annals of Allergy, Asthma and Immunology - June 11, 2023 Category: Allergy & Immunology Authors: Courtney L Ramos Hiral Thakrar Kristen Walters Jeremy Waldram Andrew A White Source Type: research
The role of oxylipins in NSAID-exacerbated respiratory disease (N-ERD)
Adv Pharmacol. 2023;97:423-444. doi: 10.1016/bs.apha.2022.12.002. Epub 2023 Jan 10.ABSTRACTNonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) is characterized by nasal polyp formation, adult-onset asthma, and hypersensitivity to all cyclooxygenase-1 (COX-1) inhibitors. Oxygenated lipids are collectively known as oxylipins and are polyunsaturated fatty acids (PUFA) oxidation products. The most extensively researched oxylipins being the eicosanoids formed from arachidonic acid (AA). There are four major classes of eicosanoids including leukotrienes, prostaglandins, thromboxanes, and lipoxins....
Source: Advances in Pharmacology - May 26, 2023 Category: Drugs & Pharmacology Authors: Kimberley Cousins Chien-Chang Chen Esha Sehanobish Elina Jerschow Source Type: research
